Evotec (GB:0IRF)
LSE:0IRF
0IRF Stock Chart & Stats
€5.49
-€0.23(-2.70%)
At close: 4:00 PM EST
€5.49
-€0.23(-2.70%)
Day’s Range― - ―
52-Week Range€4.00 - €8.57
Previous CloseN/A
Volume41.80K
Average Volume (3M)8.19K
Market Cap
€803.94M
Enterprise Value€833.65M
Total Cash (Recent Filing)€476.39M
Total Debt (Recent Filing)€447.69M
Price to Earnings (P/E)16.6
Beta1.23
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.31
Shares Outstanding177,877,780
10 Day Avg. Volume6,171
30 Day Avg. Volume8,192
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.07Price Target Upside46.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€785.14M
Bulls Say, Bears Say
Bulls Say
Business RecoveryPotential upside exists upon business recovery and as focus assets shift to later stages of development.
Debt ManagementDespite the net debt leverage ratio reaching 4.3x, management remains confident about meeting upcoming covenants.
Bears Say
Financial PerformanceThe net debt leverage ratio reached 4.3x, partly due to worsening EBITDA, indicating additional net debt reduction is needed.
Market UncertaintyThere is uncertainty over the timing of clarity on Evotec's 2025+ trajectory, with a risk that no guidance will be provided soon.
Evotec News
0IRF FAQ
What was Evotec’s price range in the past 12 months?
Evotec lowest share price was €4.00 and its highest was €8.57 in the past 12 months.
What is Evotec’s market cap?
Evotec’s market cap is €803.94M.
When is Evotec’s upcoming earnings report date?
Evotec’s upcoming earnings report date is May 06, 2026 which is in 26 days.
How were Evotec’s earnings last quarter?
Evotec released its earnings results on Apr 08, 2026. The company reported €0.31 earnings per share for the quarter, beating the consensus estimate of -€0.18 by €0.49.
Is Evotec overvalued?
According to Wall Street analysts Evotec’s price is currently Undervalued.
Does Evotec pay dividends?
Evotec does not currently pay dividends.
What is Evotec’s EPS estimate?
Evotec’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evotec have?
Evotec has 177,877,780 shares outstanding.
What happened to Evotec’s price movement after its last earnings report?
Evotec reported an EPS of €0.31 in its last earnings report, beating expectations of -€0.18. Following the earnings report the stock price went up 3.838%.
Which hedge fund is a major shareholder of Evotec?
Currently, no hedge funds are holding shares in GB:0IRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evotec Stock Smart Score
Company Description
Evotec
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
0IRF Stock 12 Month Forecast
Average Price Target
€8.07
▲(46.93% Upside)
Technical Analysis
Biofrontera
―
Biotest
―
B.R.A.I.N. Biotechnology Research and Information Network
―
Merck KGaA
―
Heidelberg Pharma AG
―
Options Prices
Currently, No data available
---